Table 2 Baseline characteristics of healthy subjects (human study, multiple-dose phase)
Parameter | LCI699 0.5 mg | LCI699 1 mg | LCI699 3 mg | Eplerenone | Placebo |
|---|---|---|---|---|---|
n = 12 | n = 12 | n = 12 | n = 10 | n = 11 | |
Age, years | 33.0 ± 6.0 | 32.1 ± 7.2 | 34.2 ± 8.1 | 32.5 ± 5.2 | 35.8 ± 7.8 |
Body weight, kg | 80.5 ± 6.1 | 76.1 ± 6.2 | 76.8 ± 6.9 | 79.2 ± 6.0 | 82.8 ± 8.6 |
Supine heart rate, bpm | 57 ± 5 | 63 ± 10 | 61 ± 5 | 62 ± 9 | 64 ± 8 |
Supine blood pressure, mmHg | 128/75 ± 8/7 | 124/73 ± 11/8 | 123/75 ± 8/4 | 124/73 ± 9/6 | 124/74 ± 9/6 |
Plasma aldosterone, pg/mL | 204.8 ± 78.7 | 186.4 ± 74.5 | 236.1 ± 85.6 | 244.9 ± 80.3 | 224.2 ± 83.5 |
Plasma cortisol, ng/mL | 120.5 ± 35.4 | 113.5 ± 28.2 | 112.9 ± 34.7 | 121.6 ± 46.1 | 103.4 ± 46.7 |
Plasma ACTH, pg/mL | 21.9 ± 6.9 | 26.0 ± 9.6 | 30.7 ± 16.6 | 26.8 ± 14.1 | 22.1 ± 14.6 |
Plasma renin activity, ng/mL/h | 1.24 ± 0.59 | 1.03 ± 0.65 | 1.00 ± 0.32 | 1.83 ± 1.36 | 1.30 ± 1.04 |
Plasma sodium, mmol/L | 140.8 ± 1.4 | 140.9 ± 1.2 | 140.8 ± 1.4 | 141.2 ± 1.3 | 140.9 ± 2.1 |
Plasma potassium, mmol/L | 4.5 ± 0.3 | 4.3 ± 0.2 | 4.5 ± 0.1 | 4.3 ± 0.3 | 4.3 ± 0.3 |
Serum creatinine, μmol/L | 94.5 ± 6.5 | 93.1 ± 10.0 | 91.5 ± 6.3 | 90.6 ± 6.9 | 92.1 ± 4.4 |
Blood glucose, mmol/L | 4.9 ± 0.5 | 4.9 ± 0.3 | 5.2 ± 0.5 | 5.2 ± 0.5 | 4.9 ± 0.7 |